Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tissue Repair Ltd ( (AU:TRP) ) has shared an announcement.
Tissue Repair Limited has appointed Mr. Dion Cohen as its new Chief Financial Officer, effective March 31, 2025, replacing Mr. Cameron Peter Jones. This strategic move marks a shift from outsourced CFO functions to having an in-house CFO, which is expected to enhance collaboration with the CEO and clinical teams, particularly in executing the Phase III trial for TR-987 and advancing the TR Pro+ product line.
More about Tissue Repair Ltd
Tissue Repair Limited (ASX:TRP) is a biotechnology company specializing in developing advanced wound healing agents. The company is currently focused on Phase 3 clinical trials for its lead drug candidate TR987® aimed at treating chronic wounds, and is also working on commercializing TR Pro+®, a topical gel designed to enhance healing post-cosmetic and medical procedures. Additionally, Tissue Repair is looking to commercialize its proprietary Glucoprime® API for various wound and skin conditions.
YTD Price Performance: -7.14%
Average Trading Volume: 34,106
Technical Sentiment Signal: Buy
Learn more about TRP stock on TipRanks’ Stock Analysis page.